{
    "clinical_study": {
        "@rank": "13379", 
        "arm_group": [
            {
                "arm_group_label": "ARM A- BBI608 in combination with FOLFOX6", 
                "arm_group_type": "Experimental", 
                "description": "BBI608 is administered orally twice daily, continuously. Oxaliplatin 85 mg/m2 together with leucovorin 400 mg/m2 will be administered intravenously. 5-FU 400 mg/m2 bolus will be administered intravenously immediately following oxaliplatin/leucovorin infusion, followed by 5-FU 1200 mg/m2/day (total 2400 mg/m2 over 46-48 hours) continuous intravenous infusion This regimen will be repeated every 14 days thereafter."
            }, 
            {
                "arm_group_label": "ARM B- BBI608 in combination with FOLFOX6 and Bevacizumab", 
                "arm_group_type": "Experimental", 
                "description": "BBI608 is administered orally twice daily, continuously. Oxaliplatin 85 mg/m2 together with leucovorin 400 mg/m2 will be administered intravenously. 5-FU 400 mg/m2 bolus will be administered intravenously immediately following oxaliplatin/leucovorin infusion, followed by 5-FU 1200 mg/m2/day (total 2400 mg/m2 over 46-48 hours) continuous intravenous infusion. Bevacizumab 5 mg/kg will be administered intravenously following oxaliplatin/leucovorin infusion. This regimen will be repeated every 14 days thereafter."
            }, 
            {
                "arm_group_label": "ARM C- BBI608 in combination with CAPOX", 
                "arm_group_type": "Experimental", 
                "description": "BBI608 is administered orally twice daily, continuously. CAPOX regimen will be administered orally (capecitabine) and IV (oxaliplatin). Capecitabine 850 mg/m2 will be administered orally twice-daily for 14 consecutive days and be repeated every 21 days. Oxaliplatin will be administered IV and be repeated every 21 days thereafter.  If capecitabine is tolerated at the 850 mg/m2 twice daily dose, dosage may be increased to 1000 mg/m2 twice daily as tolerated after the first cycle."
            }, 
            {
                "arm_group_label": "ARM D- BBI608 in combination with FOLFIRI", 
                "arm_group_type": "Experimental", 
                "description": "BBI608 is administered orally twice daily, continuously. Irinotecan 180 mg/m2 together with leucovorin 400 mg/m2 will be administered intravenously. 5-FU 400 mg/m2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m2/day (total 2400 mg/m2) continuous infusion. This regimen will be repeated every 14 days thereafter."
            }, 
            {
                "arm_group_label": "ARM E- BBI608 in combination with FOLFIRI and Bevacizumab", 
                "arm_group_type": "Experimental", 
                "description": "BBI608 is administered orally twice daily, continuously. Irinotecan 180 mg/m2 together with leucovorin 400 mg/m2 will be administered intravenously 5-FU 400 mg/m2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m2/day (total 2400 mg/m2) continuous infusion. Bevacizumab 5 mg/kg will be administered intravenously following oxaliplatin/leucovorin infusion. This regimen will be repeated every 14 days thereafter."
            }, 
            {
                "arm_group_label": "ARM F- BBI608 in combination with Regorafenib", 
                "arm_group_type": "Experimental", 
                "description": "BBI608 is administered orally twice daily, continuously. Regorafenib 120 mg will be administered orally once daily, with a low-fat meal and be continued for 21 consecutive days of every 28 days thereafter. If regorafenib is tolerated in the first cycle, dosage may be increased to 160 mg once daily as tolerated after the first cycle."
            }
        ], 
        "brief_summary": {
            "textblock": "This is an open label, multi-center, Phase Ib dose escalation study of BBI608 administered\n      in combination with either FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with\n      and without bevacizumab, or regorafenib. A study cycle will consist of daily and continuous\n      oral administration of BBI608 for four weeks (28 days) in combination with FOLFOX6 with and\n      without bevacizumab, or CAPOX or FOLFIRI with and without bevacizumab, or regorafenib."
        }, 
        "brief_title": "A Phase Ib Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer", 
        "condition": "Advance Gastrointestinal Cancer", 
        "condition_browse": {
            "mesh_term": "Gastrointestinal Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Signed written informed consent\n\n          2. A histologically confirmed solid tumor of the gastrointestinal tract including\n\n               1. Advanced unresectable, metastatic or recurrent colorectal carcinoma for which\n                  treatment with FOLFOX6 with or without bevacizumab, FOLFIRI with or without\n                  bevacizumab, CAPOX, or regorafenib would be acceptable as determined by the\n                  Investigator. Patients with colorectal carcinoma enrolling on the regorafenib\n                  arm of this study will have previously received at least two previous lines of\n                  therapy for advanced colorectal cancer, and will have previously received\n                  treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. Patients with\n                  K-ras wild type tumors enrolling on the regorafenib arm will also have\n                  previously received either cetuximab or panitumumab.\n\n               2. Hepatocellular carcinoma for which treatment with FOLFOX6 or CAPOX would be\n                  acceptable as determined by the Investigator.\n\n               3. Pancreatic adenocarcinoma for which treatment with FOLFOX6 or CAPOX would be\n                  acceptable as determined by the Investigator.\n\n               4. Cholangiocarcinoma  for which treatment with FOLFOX6 or CAPOX would be\n                  acceptable as determined by the Investigator.\n\n               5. Gastric, GEJ or esophageal adenocarcinoma for which treatment with FOLFOX6,\n                  CAPOX, or FOLFIRI would be acceptable as determined by the Investigator.\n\n          3. Patients may be treatment na\u00efve, or may have received standard chemotherapy;\n             including  regimens containing a fluoropyrimidine, or oxaliplatin, or irinotecan, or\n             regorafenib, or bevacizumab.\n\n          4. \u226518 years of age.\n\n          5. Karnofsky performance status score \u226570% (Appendix E).\n\n          6. Male or female patients of child-producing potential agree to use contraception or\n             avoidance of pregnancy measures during the study and for 30 days after the last\n             BBI608 dose.\n\n          7. Females of childbearing potential have a negative serum pregnancy test.\n\n          8. AST level \u22642.5 x ULN and ALT \u2264 2.5 \u00d7 ULN.  For patients with liver metastases, AST\n             \u22643.5 x ULN, and AST \u22643.5 x ULN may be enrolled if agreed upon by the investigator and\n             medical monitor for the sponsor.\n\n          9. Hemoglobin  \u226510 g/dl.\n\n         10. Total bilirubin level \u22641.5 \u00d7 ULN.\n\n         11. Creatinine \u22641.5 x ULN or creatinine clearance >60 mL/min/1.73 m2 for patients with\n             creatinine levels above institutional normal (as determined by Cockcroft-Gault\n             equation).\n\n         12. Absolute neutrophil count \u2265 1.5 x 109/L.\n\n         13. Platelets \u2265100 x 109/L.\n\n         14. Life expectancy estimated at \u22653 months.\n\n        Exclusion Criteria:\n\n          1. Anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents\n             within 7 days of the first dose of BBI608.\n\n          2. Major surgery within 4 weeks prior to first dose.\n\n          3. Any known untreated brain metastases.  Treated subjects must be stable for 4 weeks\n             after completion of that treatment, with image documentation required.  Patients must\n             have no clinical symptoms from brain metastases and must be either off steroids or on\n             a stable dose of steroids for at least 2 weeks prior to protocol enrollment. Patients\n             with known leptomeningeal metastases are excluded, even if treated.\n\n          4. Pregnant or breastfeeding.\n\n          5. Significant gastrointestinal disorder(s) that would, in the opinion of the Principal\n             Investigator, prevent absorption of an orally available agent\n\n          6. Unable or unwilling to swallow BBI608 capsules daily.\n\n          7. Prior treatment with BBI608.\n\n          8. Uncontrolled intercurrent illness\n\n          9. For patients to be treated with a regimen containing 5-fluorouracil/leucovorin:\n\n               1. Known hypersensitivity to 5-fluorouracil/leucovorin\n\n               2. Known dihydropyrimidine dehydrogenase (DPD) deficiency\n\n         10. For patients to be treated with a regimen containing capecitabine:\n\n               1. Known hypersensitivity to capecitabine\n\n               2. Known dihydropyrimidine dehydrogenase (DPD) deficiency\n\n               3. Significant gastrointestinal disorder(s) that would, in the opinion of the\n                  Principal Investigator, prevent absorption of an orally available agent\n\n         11. For patients to be treated with a regimen containing oxaliplatin:\n\n               1. Neurosensory neuropathy \u2265 grade 2 at baseline\n\n               2. Known hypersensitivity to oxaliplatin or other platinum containing compounds\n\n         12. For patients to be treated with a regimen containing irinotecan:\n\n               1. Known hypersensitivity to irinotecan\n\n               2. Abnormal glucuronidation of bilirubin\n\n         13. For patients to be treated with a regimen containing bevacizumab:\n\n               1. Current uncontrolled hypertension as well as prior history of hypertensive\n                  crisis or hypertensive encephalopathy\n\n               2. History of cardiac disease: congestive heart failure (CHF) > NYHA Class II;\n                  active coronary artery disease, myocardial infarction within 6 months prior to\n                  study entry; unevaluated new onset angina within 3 months or unstable angina or\n                  cardiac arrhythmias requiring anti-arrhythmic therapy\n\n               3. History of arterial thrombotic or embolic events (within 6 months prior to study\n                  entry)\n\n               4. Significant vascular disease\n\n               5. Evidence of bleeding diathesis or clinically significant coagulopathy\n\n               6. Major surgical procedure within 28 days, or anticipation of the need for major\n                  surgical procedure during the course of the study as well as minor surgical\n                  procedure within 7 days prior to study enrollment\n\n               7. Proteinuria at screening as demonstrated by urinalysis with proteinuria \u2265 2+.\n\n               8. History of abdominal fistula, gastrointestinal perforation, peptic ulcer, or\n                  intra-abdominal abscess within 6 months\n\n               9. Ongoing serious, non-healing wound, ulcer, or bone fracture\n\n              10. Known hypersensitivity to any component of bevacizumab\n\n              11. History of reversible posterior leukoencephalopathy syndrome (RPLS)\n\n         14. For patients to be treated with a regimen containing regorafenib:\n\n               1. History of cardiac disease: congestive heart failure (CHF) > NYHA Class II;\n                  active coronary artery disease, myocardial infarction within 6 months prior to\n                  study entry; unevaluated new onset angina within 3 months or unstable angina or\n                  cardiac arrhythmias requiring anti-arrhythmic therapy\n\n               2. Current uncontrolled hypertension\n\n               3. Interstitial lung disease with ongoing signs and symptoms at the time of\n                  screening\n\n               4. History of HIV infection or chronic hepatitis B or C\n\n               5. Active clinically serious infections\n\n               6. History of arterial or embolic events (within 6 months prior to study entry)\n\n               7. Liver cirrhosis \u2265 Child-Pugh class B with uncontrolled ascites\n\n               8. History of RPLS\n\n               9. Ongoing serious, non-healing wound, ulcer, or bone fracture\n\n              10. Evidence of bleeding diathesis or a clinically significant coagulopathy\n\n              11. Renal failure requiring hemo- or peritoneal dialysis\n\n              12. Persistent proteinuria of CTCAE grade 3 (>3.5g/24 hours)\n\n              13. Significant gastrointestinal disorder(s) that would, in the opinion of the\n                  Principal Investigator, prevent absorption of an orally available agent\n\n              14. Known hypersensitivity to regorafenib"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "144", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02024607", 
            "org_study_id": "BBI608-246"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "ARM A- BBI608 in combination with FOLFOX6", 
                    "ARM B- BBI608 in combination with FOLFOX6 and Bevacizumab", 
                    "ARM C- BBI608 in combination with CAPOX", 
                    "ARM D- BBI608 in combination with FOLFIRI", 
                    "ARM E- BBI608 in combination with FOLFIRI and Bevacizumab", 
                    "ARM F- BBI608 in combination with Regorafenib"
                ], 
                "intervention_name": "BBI608", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "ARM A- BBI608 in combination with FOLFOX6", 
                    "ARM B- BBI608 in combination with FOLFOX6 and Bevacizumab", 
                    "ARM D- BBI608 in combination with FOLFIRI", 
                    "ARM E- BBI608 in combination with FOLFIRI and Bevacizumab"
                ], 
                "intervention_name": "Fluorouracil", 
                "intervention_type": "Drug", 
                "other_name": [
                    "5-FU", 
                    "Carac", 
                    "Efudex", 
                    "Fluoroplex", 
                    "Adrucil"
                ]
            }, 
            {
                "arm_group_label": [
                    "ARM A- BBI608 in combination with FOLFOX6", 
                    "ARM B- BBI608 in combination with FOLFOX6 and Bevacizumab", 
                    "ARM C- BBI608 in combination with CAPOX"
                ], 
                "intervention_name": "Oxaliplatin", 
                "intervention_type": "Drug", 
                "other_name": "Eloxatin"
            }, 
            {
                "arm_group_label": [
                    "ARM A- BBI608 in combination with FOLFOX6", 
                    "ARM B- BBI608 in combination with FOLFOX6 and Bevacizumab", 
                    "ARM D- BBI608 in combination with FOLFIRI", 
                    "ARM E- BBI608 in combination with FOLFIRI and Bevacizumab"
                ], 
                "intervention_name": "Leucovorin", 
                "intervention_type": "Drug", 
                "other_name": "Folinic Acid"
            }, 
            {
                "arm_group_label": [
                    "ARM D- BBI608 in combination with FOLFIRI", 
                    "ARM E- BBI608 in combination with FOLFIRI and Bevacizumab"
                ], 
                "intervention_name": "Irinotecan", 
                "intervention_type": "Drug", 
                "other_name": "Camptosar"
            }, 
            {
                "arm_group_label": [
                    "ARM B- BBI608 in combination with FOLFOX6 and Bevacizumab", 
                    "ARM E- BBI608 in combination with FOLFIRI and Bevacizumab"
                ], 
                "intervention_name": "Bevacizumab", 
                "intervention_type": "Drug", 
                "other_name": "Avastin"
            }, 
            {
                "arm_group_label": "ARM C- BBI608 in combination with CAPOX", 
                "intervention_name": "Capecitabine", 
                "intervention_type": "Drug", 
                "other_name": "Xeloda"
            }, 
            {
                "arm_group_label": "ARM F- BBI608 in combination with Regorafenib", 
                "intervention_name": "Regorafenib", 
                "intervention_type": "Drug", 
                "other_name": "Stivarga"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fluorouracil", 
                "Capecitabine", 
                "Oxaliplatin", 
                "Irinotecan", 
                "Bevacizumab", 
                "Leucovorin", 
                "Levoleucovorin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 27, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Mayo Clinic Clinical Trials Office", 
                    "phone": "507-538-7623"
                }, 
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85259"
                    }, 
                    "name": "Mayo Clinic Campus in Arizona"
                }, 
                "investigator": {
                    "last_name": "Thorvardur R Halfdanarson, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Mayo Clinic Clinical Trials Office", 
                    "phone": "507-538-7623"
                }, 
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55901"
                    }, 
                    "name": "Mayo Clinic"
                }, 
                "investigator": {
                    "last_name": "Joleen M Hubbard, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "jkueber@ghs.org", 
                    "last_name": "Jan Kueber, RN", 
                    "phone": "864-455-3600"
                }, 
                "facility": {
                    "address": {
                        "city": "Greenville", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29605"
                    }, 
                    "name": "Institute for Translational Oncology Research, Greenville Health System"
                }, 
                "investigator": {
                    "last_name": "William J Edenfield, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Derek Jonker, MD", 
                    "phone": "613-737-7700"
                }, 
                "facility": {
                    "address": {
                        "city": "Ottawa", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "K1H 8L6"
                    }, 
                    "name": "Ottawa Hospital Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Derek Jonker, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_arms": "6", 
        "overall_official": {
            "affiliation": "Boston Biomedical, Inc", 
            "last_name": "Boston Biomedical", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Assessment of safety of BBI608 administered in combination with either FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with and without bevacizumab, or regorafenib to patients with advanced gastrointestinal malignancies by reporting of adverse events and serious adverse events", 
            "measure": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "Adverse events will be assessed at baseline, while the participant is taking BBI608, and for 30 days after stopping therapy. The average length of this duration is expected to be approximately 4 months."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02024607"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Blood sampling to assess the pharmacokinetic profile  of BBI608 administered in combination with either FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with and without bevacizumab, or regorafenib.", 
                "measure": "Assess pharmacokinetic profile", 
                "safety_issue": "No", 
                "time_frame": "During the first 28 days of treatment"
            }, 
            {
                "description": "Tumor Biopsy(s) to provide information on analysis of the targets and downstream genes/ effect of BBI608 on cancer stem cells through immunohistochemistry.", 
                "measure": "Assess pharmacodynamic activity", 
                "safety_issue": "No", 
                "time_frame": "During the first 28 days of treatment"
            }, 
            {
                "description": "To assess the preliminary anti-tumor activity of BBI608 administered in combination with either FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with and without bevacizumab, or regorafenib.", 
                "measure": "Anti-tumor activity", 
                "safety_issue": "No", 
                "time_frame": "Anti-tumor activity is assessed every 8 weeks, from the first dose of BBI608 to 30 days after the last dose of BBI608, an expected average of 5 months"
            }
        ], 
        "source": "Boston Biomedical, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boston Biomedical, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}